Barrett's oesophagus: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 0
• GLP-1 0
• AKT 0
• COX-2 0
• CTNNB1 0
• GIP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 128 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Endorotor Resection In Refractory Barrett's Dysplasia Patients

  NCT03364114· Interscope, Inc.· Updated 27 Mar 2026

  “POOR RECRUITMENT”Registry text, quoted unchanged. Source

• Withdrawn

  Imaging of the Esophagus Using a SECM Capsule

  NCT03546660· Massachusetts General Hospital· Updated 22 Oct 2025

  “We are currently working and developing our technology to ensure accurate data collection and safety. We will re-open in the future for recruitment.”Registry text, quoted unchanged. Source

• Suspended

  Acetic Acid for the Detection of Esophageal Neoplasms

  NCT04054713· Coordinación de Investigación en Salud, Mexico· Updated 24 Apr 2025

  “not enough patients enrolled”Registry text, quoted unchanged. Source

• Terminated

  Systems Biology of Gastrointestinal and Related Diseases

  NCT05579444· Viome· Updated 15 Dec 2023

  “Lack of enrollment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Obeticholic Acid for Prevention in Barrett's Esophagus

  NCT04939051· National Cancer Institute (NCI)· Source

• Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  NCT06732388· National Cancer Institute (NCI)· Source

• The Johns Hopkins Heartburn Center Registry

  NCT03853772· Johns Hopkins University· Source

• InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

  NCT05463796· Dana-Farber Cancer Institute· Source

• Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

  NCT05530343· University of Colorado, Denver· Source

• Development of Fluorescent Lectin Tracers With Dedicated Technology for in Vivo Detection of Esophageal Dysplasia in Barrett Patients

  NCT07643727· University Medical Center Groningen· Source

• Enhancing Screening Practices for BE

  NCT07335445· Rutgers, The State University of New Jersey· Source

• Biomarkers of Airway Disease, Barrett's and Underdiagnosed Reflux Noninvasively (BADBURN)

  NCT05216133· NYU Langone Health· Source

• GCC Agonist Signal in the Small Intestine

  NCT05107219· University of Wisconsin, Madison· Source

• Detection of Barrett s Esophagus in Patients Without GERD Symptoms

  NCT04880044· Case Comprehensive Cancer Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Mendelian Randomization Analysis 3
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 1
• Flow Cytometry 3
• Immunohistochemistry 7
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Machine Learning 3
• Deep Learning 1
• Cohort Studies 14
• Genome-Wide Association Study 5

• Optimising Expert Pathology Referral in Barrett's Oesophagus Dysplasia Through p53-Guided Triage: A Nationwide Real-World Cohort Study.

  United European Gastroenterol J, Oct 2026

• Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel (DEPP).

  Histopathology, Jun 2026

• Ancillary Studies in the Diagnosis and Classification of Barrett Esophagus: What's on the Menu?

  Surg Pathol Clin, Jun 2026

• Aberrant p53 expression, a stronger risk factor for neoplastic progression in Barrett's esophagus than confirmed low grade dysplasia: a large multicenter prospective cohort study.

  Endoscopy, Jun 2026

• The Utility of Mucin 2 and Caudal-Type Homeobox Transcription Factor 2 Expression in the Diagnosis of Barrett's Esophagus: A Community-Based Study of Wide-Area Transepithelial Sampling and Forceps Biopsies.

  Am J Gastroenterol, Jan 2026

• Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.

  Am J Gastroenterol, Feb 2025

• The usefulness of chromoendoscopy with methylene blue in Barrett's metaplasia and early esophageal carcinoma.

  Surg Endosc, Mar 2008

See which targets of this disease your abstract mentions, and go to the people working on them.